Company
Novo Nordisk
Official Name: Novo Nordisk A/S
Headquarters: Bagsvaerd, Denmark
Founded: December 21, 1923
Employees: 47,792
CEO: Mr. Lars Fruergaard Jorgensen
Market Cap
kr.2.120 Trillion
DKK as of Jan. 1, 2023
US$304.61 Billion
Novo Nordisk Categories
Denmark
languages
Healthcare
languages
Biotechnology
Denmark Healthcare
Denmark Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
CSL Limited
|
$93.24 B |
Regeneron Pharmaceuticals, Inc.
|
$79.53 B |
| Marinomed Biotech AG | $76.72 B |
|
Vertex Pharmaceuticals Incorporated
|
$74.13 B |
|
Moderna, Inc.
|
$68.42 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Pfizer
|
$287.63 B |
|
AbbVie
|
$285.80 B |
Detailed Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Stocks & Indices
Novo Nordisk A/S has the following listings and related stock indices.
Stock: OMXC: NOVO.B
Stock: Bovespa: N1VO34
Stock: NYSE: NVO
Stock: BMV: NVON
Stock: FSX: NOVC
Stock: XETR: NOVC
Stock: XETR: NOVA
Stock: FSX: NOVA
Product & Services
Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda
Key People
Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO)
Financials
Revenue: DKK 140.80 billion (2021)
Operating income: DKK 52.483 billion (2019)
Net income: DKK 38.951 billion (2019)
Total assets: DKK 125.612 billion (2019)
Total equity: DKK 57.593 billion (2019)